Erythrokinetics

Translation of potential therapies in the diverse hemoglobinopathy population is likely affected by underlying molecular mutations, genetic modifier traits[42 –50 ], and by physiologic factors such as erythrokinetics and endogenous erythropoeitin levels[6 ].